Complete financial analysis of RaySearch Laboratories AB (publ) (RSLBF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RaySearch Laboratories AB (publ), a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- Garibaldi Resources Corp. (GGIFF) Income Statement Analysis – Financial Results
- PT Golden Energy Mines Tbk (GEMS.JK) Income Statement Analysis – Financial Results
- SuperRobotics Holdings Limited (8176.HK) Income Statement Analysis – Financial Results
- Metalink Ltd. (MTLK) Income Statement Analysis – Financial Results
- Resource Base Limited (RBX.AX) Income Statement Analysis – Financial Results
RaySearch Laboratories AB (publ) (RSLBF)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.raysearchlabs.com
About RaySearch Laboratories AB (publ)
RaySearch Laboratories AB (publ), a medical technology company, develops software solutions for cancer treatment worldwide. It develops and markets RayStation, a treatment planning system for treatment activities, such as automated planning, adaptive therapy, multi-criteria optimization, fast and accurate dose computations, OAR dose reduction, robustness, machine learning, VMAT, IMRT, 3D-CRT, virtual simulation, electron beam therapy, tomotherapy, stereotactic, proton therapy, carbon ion therapy, and boron neutron capture therapy. The company also develops RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy; and RayCare, an oncology information system to support cancer treatment activities. In addition, it offers RayCommand, a treatment control system that is compatible with various hardware models and supports advanced functionalities of treatment machines and software systems; and RayIntelligence, a cloud-based oncology analytics system that turns patient data into insights. Further, the company provides training courses related to its products. RaySearch Laboratories AB (publ) is headquartered in Stockholm, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.02B | 843.65M | 641.67M | 651.61M | 741.58M | 627.22M | 585.09M | 531.47M | 397.60M | 285.22M | 204.47M | 182.09M | 126.10M | 117.73M | 83.69M | 62.69M | 64.71M | 68.98M | 69.86M | 39.48M | 22.15M |
| Cost of Revenue | 106.58M | 94.99M | 50.40M | 43.37M | 72.37M | 56.02M | 36.65M | 26.87M | 23.69M | 11.63M | 6.06M | 3.03M | 442.00K | 92.00K | 1.01M | 661.00K | 863.00K | 849.00K | 1.12M | 1.24M | 1.75M |
| Gross Profit | 915.58M | 748.66M | 591.28M | 608.24M | 669.22M | 571.20M | 548.44M | 504.60M | 373.91M | 273.59M | 198.41M | 179.06M | 125.66M | 117.64M | 82.67M | 62.03M | 63.84M | 68.13M | 68.73M | 38.24M | 20.39M |
| Gross Profit Ratio | 89.57% | 88.74% | 92.15% | 93.34% | 90.24% | 91.07% | 93.74% | 94.94% | 94.04% | 95.92% | 97.04% | 98.34% | 99.65% | 99.92% | 98.79% | 98.95% | 98.67% | 98.77% | 98.40% | 96.86% | 92.08% |
| Research & Development | 237.74M | 238.77M | 233.44M | 185.04M | 174.67M | 147.69M | 104.30M | 93.21M | 101.51M | 95.07M | 90.72M | 78.66M | 57.58M | 53.50M | 24.72M | 29.18M | 24.23M | 11.56M | 11.05M | 10.80M | 3.30M |
| General & Administrative | 195.16M | 171.72M | 122.04M | 106.29M | 100.14M | 91.98M | 63.25M | 66.29M | 43.24M | 30.74M | 80.11M | 39.28M | 21.37M | 17.76M | 12.69M | 11.03M | 12.53M | 11.57M | 11.17M | 11.00M | 8.92M |
| Selling & Marketing | 362.85M | 309.42M | 300.19M | 291.23M | 345.43M | 261.91M | 204.85M | 156.84M | 138.36M | 78.43M | 53.02M | 36.27M | 19.22M | 4.69M | 3.60M | 2.56M | 1.37M | 2.17M | 1.42M | 1.14M | 918.00K |
| SG&A | 558.01M | 481.14M | 422.23M | 397.52M | 445.56M | 353.89M | 268.10M | 223.13M | 181.60M | 109.17M | 133.13M | 75.55M | 40.58M | 22.44M | 16.30M | 13.59M | 13.89M | 13.74M | 12.58M | 12.13M | 9.83M |
| Other Expenses | 4.96M | -1.56M | -353.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -122.00K | 1.82M | 799.00K | -1.81M | -55.00K | 5.87M | 8.89M | 500.00K | -948.00K |
| Operating Expenses | 800.70M | 718.35M | 655.32M | 582.56M | 620.23M | 501.59M | 372.40M | 316.34M | 283.11M | 204.24M | 223.85M | 154.20M | 98.04M | 77.76M | 41.81M | 40.97M | 38.06M | 31.17M | 32.52M | 23.44M | 12.19M |
| Cost & Expenses | 907.28M | 813.34M | 705.72M | 625.93M | 692.60M | 557.61M | 409.05M | 343.21M | 306.80M | 215.87M | 229.91M | 157.23M | 98.48M | 77.86M | 42.83M | 41.63M | 38.92M | 32.02M | 33.64M | 24.68M | 13.94M |
| Interest Income | 4.90M | 1.11M | 708.00K | 2.74M | 1.26M | 283.00K | 368.00K | 19.00K | 260.00K | 314.00K | 852.00K | 412.00K | 1.11M | 252.00K | 425.00K | 3.10M | 2.57M | 1.34M | 474.00K | 238.00K | 799.00K |
| Interest Expense | 9.69M | 11.48M | 6.04M | 5.70M | 6.74M | 2.28M | 2.16M | 1.51M | 2.13M | 973.00K | 97.00K | 36.00K | 29.00K | 3.00K | 4.00K | 49.00K | 310.00K | 19.00K | -1.07M | 80.00K | 48.00K |
| Depreciation & Amortization | 286.15M | 296.99M | 250.00M | 76.55M | 68.88M | 18.23M | 70.79M | 67.34M | 50.00M | 54.00M | 53.00M | 48.50M | 1.11M | 252.00K | 425.00K | 3.10M | 2.57M | 5.98M | 5.21M | 238.00K | 12.10M |
| EBITDA | 405.93M | 340.85M | 197.36M | 75.82M | 138.31M | 112.97M | 230.83M | 266.93M | 145.62M | 133.67M | 28.13M | 68.60M | 62.97M | 40.13M | 41.29M | 24.16M | 28.35M | 40.85M | 45.29M | 15.04M | 9.00M |
| EBITDA Ratio | 39.71% | 40.40% | 30.76% | 32.72% | 34.03% | 33.01% | 38.98% | 50.16% | 36.62% | 46.87% | 13.76% | 39.60% | 22.78% | 34.08% | 49.34% | 38.53% | 43.82% | 59.20% | 64.74% | 38.10% | 40.66% |
| Operating Income | 114.88M | 42.74M | -52.64M | -782.00K | 68.17M | 69.61M | 159.67M | 199.56M | 95.34M | 79.36M | -25.72M | 22.55M | 27.62M | 39.87M | 40.86M | 21.06M | 25.78M | 33.54M | 39.61M | 14.80M | -3.10M |
| Operating Income Ratio | 11.24% | 5.07% | -8.20% | -0.12% | 9.19% | 11.10% | 27.29% | 37.55% | 23.98% | 27.82% | -12.58% | 12.38% | 21.91% | 33.87% | 48.83% | 33.59% | 39.84% | 48.63% | 56.70% | 37.50% | -13.99% |
| Total Other Income/Expenses | -4.79M | -10.37M | -5.33M | -3.01M | -5.56M | -3.70M | -3.77M | -1.47M | -1.85M | -659.00K | 754.00K | 1.02M | 1.08M | 249.00K | 421.00K | 3.05M | 2.26M | 1.32M | 408.00K | 158.00K | 751.00K |
| Income Before Tax | 110.09M | 32.38M | -58.67M | -6.48M | 62.61M | 90.76M | 155.90M | 198.09M | 93.49M | 78.70M | -24.97M | 23.56M | 28.70M | 40.12M | 41.28M | 24.11M | 28.04M | 34.86M | 40.02M | 14.96M | -2.35M |
| Income Before Tax Ratio | 10.77% | 3.84% | -9.14% | -0.99% | 8.44% | 14.47% | 26.65% | 37.27% | 23.51% | 27.59% | -12.21% | 12.94% | 22.76% | 34.08% | 49.33% | 38.45% | 43.34% | 50.54% | 57.28% | 37.90% | -10.60% |
| Income Tax Expense | 28.52M | 8.60M | -11.36M | 2.60M | 12.20M | 12.24M | 38.27M | 46.68M | 23.28M | 18.87M | -4.13M | 3.70M | 11.70M | 11.23M | 11.14M | 5.88M | 8.26M | -1.36M | 10.87M | 2.06M | 2.68M |
| Net Income | 81.57M | 23.78M | -47.32M | -9.08M | 50.41M | 78.52M | 117.63M | 151.41M | 70.21M | 59.83M | -20.84M | 19.86M | 17.01M | 28.90M | 30.15M | 18.22M | 19.78M | 36.22M | 29.14M | 12.90M | -5.02M |
| Net Income Ratio | 7.98% | 2.82% | -7.37% | -1.39% | 6.80% | 12.52% | 20.10% | 28.49% | 17.66% | 20.98% | -10.19% | 10.91% | 13.49% | 24.54% | 36.02% | 29.07% | 30.57% | 52.51% | 41.72% | 32.68% | -22.68% |
| EPS | 2.38 | 0.69 | -1.38 | -0.26 | 1.47 | 2.29 | 3.43 | 4.42 | 2.05 | 1.75 | -0.61 | 0.58 | 0.50 | 0.84 | 0.88 | 0.53 | 0.58 | 1.06 | 0.85 | 0.41 | -0.34 |
| EPS Diluted | 2.38 | 0.69 | -1.38 | -0.26 | 1.47 | 2.29 | 3.43 | 4.42 | 2.05 | 1.75 | -0.61 | 0.58 | 0.50 | 0.84 | 0.88 | 0.53 | 0.57 | 1.05 | 0.85 | 0.38 | -0.31 |
| Weighted Avg Shares Out | 34.28M | 34.28M | 34.28M | 34.28M | 34.28M | 34.28M | 34.28M | 34.28M | 34.28M | 34.28M | 34.05M | 33.98M | 34.28M | 34.28M | 34.28M | 34.28M | 34.28M | 34.28M | 34.09M | 31.54M | 14.76M |
| Weighted Avg Shares Out (Dil) | 34.28M | 34.28M | 34.28M | 34.28M | 34.28M | 34.28M | 34.28M | 34.28M | 34.28M | 34.28M | 34.05M | 33.98M | 34.28M | 34.28M | 34.28M | 34.28M | 34.49M | 34.45M | 34.18M | 34.28M | 15.98M |
RaySearch Laboratories to present ongoing development in liver ablation therapy* at RSNA 2024
STOCKHOLM , Nov. 29, 2024 /PRNewswire/ -- RaySearch will be exhibiting its advanced software solutions at RSNA in Chicago, Illinois, December 1 – 4. RSNA is the largest conference show in the field of radiology which opens new horizons for...
RaySearch Laboratories: Interim report July - September 2024
STOCKHOLM , Nov. 8, 2024 /PRNewswire/ -- THIRD QUARTER (JULY - SEPTEMBER 2024) Order intake SEK 253.4 M (240.7) Net sales SEK 293.3 (252.9) Operating profit SEK 61.8 M (28,6) Profit after tax SEK 45.4 M (21,6) Earnings per share...
RaySearch Laboratories: Interim report April - June 2024
STOCKHOLM , Aug. 16, 2024 /PRNewswire/ -- SECOND QUARTER (APRIL- JUNE 2024) Order intake SEK 290.3 M (239.2) Net sales SEK 318.9 M (239.5) Operating profit SEK 79.3 M (18.2) Profit after tax SEK 61.4 M (10.9) Earnings per share before/after dilution SEK...
RaySearch Laboratories: Interim report January 1 - March 31, 2024
STOCKHOLM , May 17, 2024 /PRNewswire/ -- FIRST QUARTER (JANUARY - MARCH 2024) Oder intake SEK 238.5 M (206.6) Net sales SEK 257.2 M (230.2) Operating profit SEK 45.8 M (23.7) Profit after tax SEK 36.7 M (17.6) Earnings per...
RaySearch Laboratories: Year-end report 2023
STOCKHOLM , Feb. 23, 2024 /PRNewswire/ -- FOURTH QUARTER (OCTOBER - DECEMBER 2023) Order intake SEK 317.7 M (514.4) Net sales SEK 299.6 M (264.4) Operating profit SEK 44.4 M (20.7) Profit after tax SEK 31.5 M (14.1) Earnings per...
RaySearch Laboratories: Interim report January 1 - September 30, 2023
STOCKHOLM , Nov. 17, 2023 /PRNewswire/ -- THIRD QUARTER (JULY - SEPTEMBER 2023) Order intake SEK 240.7 M (219.1) Net sales SEK 252.9 M (210.9) Operating profit SEK 28.6 M (12.0) Profit after tax SEK 21.6 M (10.1) Earnings per...
Invitation to presentation of RaySearch's interim report for the third quarter of 2023
STOCKHOLM , Oct. 30, 2023 /PRNewswire/ -- Analysts, investors, and the media are invited to a presentation of RaySearch's interim report for the third quarter of 2023 on November 17, 2023, at 10.00 am CET. The report will be published on...
RaySearch Laboratories : Interim report January 1 - June 30, 2023
STOCKHOLM , Aug. 25, 2023 /PRNewswire/ -- SECOND QUARTER (APRIL-JUNE 2023) Order intake SEK 239.2 M (212.5) Net sales SEK 239.5 M (160.2) Operating profit SEK 18.2 M (-19.5) Profit after tax SEK 10.9 M (-19.7) Earnings per share before/after...
Invitation to presentation of RaySearch's interim report for the second quarter of 2023
STOCKHOLM , Aug. 8, 2023 /PRNewswire/ -- Analysts, investors, and the media are invited to a presentation of RaySearch's interim report for the second quarter of 2023 on August 25, 2023, at 10.00 am CEST. The report will be published on August...
UMCG in the Netherlands purchases Micro-RayStation for pre-clinical research, RaySearch Laboratories
STOCKHOLM , July 7, 2023 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that University Medical Center Groningen (UMCG) in the Netherlands has placed an order for Micro-RayStation (μ-RayStation), RaySearch's research software platform for radiation treatment planning and plan evaluation in...
Source: https://incomestatements.info
Category: Stock Reports